JIN A04
Alternative Names: JIN-A04; YH-42946Latest Information Update: 11 Aug 2025
At a glance
- Originator J Ints Bio
- Developer Yuhan
- Class Antineoplastics
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Non-small cell lung cancer; Solid tumours
Most Recent Events
- 02 Oct 2024 Phase-I/II clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT06616766)
- 02 Oct 2024 Phase-I/II clinical trials in Non-small cell lung cancer (Metastatic disease, Late-stage disease, Second-line therapy or greater) in South Korea (PO) (NCT06616766)
- 02 Oct 2024 Phase-I/II clinical trials in Solid tumours (Metastatic disease, Late-stage disease, Second-line therapy or greater) in South Korea, USA (PO) (NCT06616766)